JoVE Logo
教师资源中心

登录

Compound Administration III

Overview

Source: Kay Stewart, RVT, RLATG, CMAR; Valerie A. Schroeder, RVT, RLATG. University of Notre Dame, IN

There are many commonly used routes for compound administration in laboratory mice and rats. However, certain protocols may require the use of less commonly used routes, including intradermal, intranasal, and intracranial injections. Specialized training is essential for these procedures to be performed successfully. Justification for these routes may need to be provided to gain Institutional Animal Care and Use Committee (IACUC) approval.

Procedure

1. Intradermal administration

  1. Most intradermal injections are aqueous-based compounds. The solutions must be physiologically buffered to have a neutral pH, in order to avoid tissue necrosis at the injection site.
  2. The needle size range is 25-30 gauge, the smallest possible.
  3. The dose range per injection site is 50-100 µL. Injecting excessive volumes can result in necrosis at the injection site or leakage of the compound out of the site due to pressure.
  4. For accurate placement o

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Application and Summary

The administration of compounds into animals can have a significant effect on both the wellbeing of the animal and the outcome of the experimental data and scientific value. The proper method of delivery is essential to the success of the experiment. Many factors must be considered to determine the best route, including the scientific aim of the study, the pH of the substance, the required dosage volume, the viscosity of the substance, and the wellbeing of the animals. Technical expertise is also a requirement for all in

Log in or to access full content. Learn more about your institution’s access to JoVE content here

References
  1. Turner, P.V., Pekow, C., Vasbinder, M. A., and Brabb, T. 2011. Administration of substances to laboratory animals: equipment and considerations, vehicle selection, and solution preparation. JAALAS. 50: 614-627.
  2. Dhuria, S.V., Hanson, L.R., and Frey II, W.H. 2010. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. Journal of Pharmaceutical Sciences. 99: 1654-1673.
  3. Stevens, J., Suidgeest, E, Van der Graaf, P.H., Danhof, M., and De Lange, E.C. 2008. Development and evaluation of a new, minimal-stress animal model for intranasal administration in freely moving rats. Poster presentation at American Association of Pharmaceutical Scientists Annual Meeting, Atlanta, Georgia.
  4. Morton, D.A., Jennings, M., Buckwell, A., Ewbank, R., Godfrey, C., Holgate, B., Inglis, I., James, R., Page, C., Sharman, I., Verschoyle, R., Westall, L., and Wilson, A.B. 2001. Refining procedures for the administration of substances Report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. Members of the Joint Working Group on Refinement. Laboratory Animals. 35: 1-41.
Tags
Compound AdministrationExperimental ApproachesRodentsRoutes Of AdministrationIntradermalIntranasalIntracranialBiomedical ResearchersSpecialized TrainingConsiderationsSafetySuccess Of ExperimentIntradermal InjectionsEpidermisDermisInflammationBlood Flow DiagnosticsAllergenic ReactionsSterile TechniquePhysiologically Buffered Solution

跳至...

0:00

Overview

1:09

Considerations for the Specialized Injections

4:46

Intradermal Administration

6:30

Intranasal Administration

7:59

Intracranial Administration in Neonatal Rodents

10:38

Applications

11:56

Summary

JoVE Logo

政策

使用条款

隐私

科研

教育

关于 JoVE

版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。